CN106729652A - 一种治疗抑郁症的西药组合物及其制备方法 - Google Patents
一种治疗抑郁症的西药组合物及其制备方法 Download PDFInfo
- Publication number
- CN106729652A CN106729652A CN201611077607.5A CN201611077607A CN106729652A CN 106729652 A CN106729652 A CN 106729652A CN 201611077607 A CN201611077607 A CN 201611077607A CN 106729652 A CN106729652 A CN 106729652A
- Authority
- CN
- China
- Prior art keywords
- parts
- western medicine
- gains
- medicine compound
- depression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 44
- 150000001875 compounds Chemical class 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 20
- 229930003270 Vitamin B Natural products 0.000 claims abstract description 19
- 239000007788 liquid Substances 0.000 claims abstract description 19
- 235000019156 vitamin B Nutrition 0.000 claims abstract description 19
- 239000011720 vitamin B Substances 0.000 claims abstract description 19
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims abstract description 18
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims abstract description 18
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229960001534 risperidone Drugs 0.000 claims abstract description 18
- RXKMOPXNWTYEHI-RDRKJGRWSA-N Flunarizine hydrochloride Chemical compound Cl.Cl.C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 RXKMOPXNWTYEHI-RDRKJGRWSA-N 0.000 claims abstract description 17
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229960000836 amitriptyline Drugs 0.000 claims abstract description 17
- 239000012153 distilled water Substances 0.000 claims abstract description 17
- 229960002807 flunarizine hydrochloride Drugs 0.000 claims abstract description 17
- 229960004801 imipramine Drugs 0.000 claims abstract description 17
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims abstract description 17
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 claims abstract description 17
- 229960000698 nateglinide Drugs 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 claims abstract description 16
- OBZHEBDUNPOCJG-SZTGPWMUSA-N carbenoxolone Chemical compound C([C@H]1C2=CC(=O)[C@@H]34)[C@](C)(C(O)=O)CC[C@@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@H]1[C@@]3(C)CC[C@@H](OC(=O)CCC(O)=O)C1(C)C OBZHEBDUNPOCJG-SZTGPWMUSA-N 0.000 claims abstract description 16
- 229960000530 carbenoxolone Drugs 0.000 claims abstract description 16
- 229960000762 perphenazine Drugs 0.000 claims abstract description 16
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 13
- UYUXSRADSPPKRZ-SKNVOMKLSA-N D-glucurono-6,3-lactone Chemical compound O=C[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@H]1O UYUXSRADSPPKRZ-SKNVOMKLSA-N 0.000 claims abstract description 12
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229950002441 glucurolactone Drugs 0.000 claims abstract description 12
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims abstract description 12
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims abstract description 12
- 239000000843 powder Substances 0.000 claims description 16
- 238000003756 stirring Methods 0.000 claims description 16
- 208000020401 Depressive disease Diseases 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- 235000019082 Osmanthus Nutrition 0.000 claims 1
- 241000333181 Osmanthus Species 0.000 claims 1
- GDXWHFPKFUYWBE-UHFFFAOYSA-N [F].Cl Chemical compound [F].Cl GDXWHFPKFUYWBE-UHFFFAOYSA-N 0.000 claims 1
- 229960000326 flunarizine Drugs 0.000 claims 1
- SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 7
- 230000036039 immunity Effects 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 8
- 229910052708 sodium Inorganic materials 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 7
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 150000002596 lactones Chemical class 0.000 description 3
- 230000000994 depressogenic effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000006996 mental state Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XARVANDLQOZMMJ-CHHVJCJISA-N 2-[(z)-[1-(2-amino-1,3-thiazol-4-yl)-2-oxo-2-(2-oxoethylamino)ethylidene]amino]oxy-2-methylpropanoic acid Chemical group OC(=O)C(C)(C)O\N=C(/C(=O)NCC=O)C1=CSC(N)=N1 XARVANDLQOZMMJ-CHHVJCJISA-N 0.000 description 1
- 206010050013 Abulia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 101100189582 Dictyostelium discoideum pdeD gene Chemical group 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 208000027626 Neurocognitive disease Diseases 0.000 description 1
- 101150098694 PDE5A gene Chemical group 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
- C12Y301/04001—Phosphodiesterase I (3.1.4.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种治疗抑郁症的西药组合物,包括以下重量份数的原料:丙咪嗪0.5‑2份,羧甲基纤维素钠2‑5份,阿米替林1‑8份,磷酸二酯酶1‑5份,那格列奈2‑5份,盐酸氟桂利嗪口服液2‑8份,葡醛内酯片2‑5份,甘珀酸钠2‑5份,瓜蒂素2‑5份,利培酮0.5‑2份,奋乃静0.5‑1份,维生素B 0.5‑1份,蒸馏水50‑100份。该西药组合物通过原料复配发挥协同作用,具有疗效好、治疗周期短、毒副作用小、无并发症产生的优点,且制备方法简单,生产成本低,可以有效增强人体免疫力,是一种有效治疗抑郁症的药物;且口感好,有利于患者长期坚持服用。
Description
技术领域
本发明涉及一种西药组合物,具体是一种治疗抑郁症的西药组合物。
背景技术
抑郁症又称抑郁障碍,以显著而持久的心境低落为主要临床特征,是心境障碍的主要类型。临床可见心境低落与其处境不相称,情绪的消沉可以从闷闷不乐到悲痛欲绝,自卑抑郁,甚至悲观厌世,可有自杀企图或行为;甚至发生木僵;部分病例有明显的焦虑和运动性激越;严重者可出现幻觉、妄想等精神病性症状。每次发作持续至少2周以上、长者甚或数年,多数病例有反复发作的倾向,每次发作大多数可以缓解,部分可有残留症状或转为慢性。
迄今,抑郁症的病因并不清楚,但可以肯定的是,生物、心理与社会环境诸多方面因素参与了抑郁症的发病过程。生物学因素主要涉及遗传、神经生化、神经内分泌、神经再生等方面;与抑郁症关系密切的心理学易患素质是病前性格特征,如抑郁气质。成年期遭遇应激性的生活事件,是导致出现具有临床意义的抑郁发作的重要触发条件。然而,以上这些因素并不是单独起作用的,目前强调遗传与环境或应激因素之间的交互作用、以及这种交互作用的出现时点在抑郁症发生过程中具有重要的影响。
发明内容
本发明的目的在于提供一种治疗抑郁症的西药组合物,以解决上述背景技术中提出的问题。
为实现上述目的,本发明提供如下技术方案:
一种治疗抑郁症的西药组合物,包括以下重量份数的原料:丙咪嗪0.5-2份,羧甲基纤维素钠2-5份,阿米替林1-8份,磷酸二酯酶1-5份,那格列奈2-5份,盐酸氟桂利嗪口服液2-8份,葡醛内酯片2-5份,甘珀酸钠2-5份,瓜蒂素2-5份,利培酮0.5-2份,奋乃静0.5-1份,维生素B 0.5-1份,蒸馏水50-100份。
作为本发明进一步的方案:包括以下重量份数的原料:丙咪嗪0.8份,羧甲基纤维素钠3份,阿米替林5份,磷酸二酯酶2份,那格列奈3份,盐酸氟桂利嗪口服液5份,葡醛内酯片3份,甘珀酸钠4份,瓜蒂素3份,利培酮1份,奋乃静0.6份,维生素B 0.7份,蒸馏水80份。
一种治疗抑郁症的西药组合物的制备方法,具体步骤为:
(1)按照重量份数称取各原料,备用;
(2)将利培酮、奋乃静研磨成粉末后加入丙咪嗪中,搅拌混合均匀;
(3)将步骤(2)所得物在60-75℃温度下烘干;
(4)将阿米替林、那格列奈、葡醛内酯片和甘珀酸钠混合后粉碎成粉末,搅拌均匀;
(5)将瓜蒂素、磷酸二酯酶和维生素B分别研磨成粉末,并在0-5℃下搅拌混合5-10min;
(6)将步骤(5)所得物和步骤(3)所得物加入盐酸氟桂利嗪口服液中,混合搅拌10-15min后加入羧甲基纤维素钠,继续搅拌5-10min;
(7)将步骤(6)所得物放入蒸馏水中,搅拌均匀后,经过压丸、定型、干燥得到西药组合物。
作为本发明再进一步的方案:所述步骤(3)将步骤(2)所得物在65℃温度下烘干。
作为本发明再进一步的方案:所述步骤(5)将瓜蒂素、磷酸二酯酶和维生素B分别研磨成粉末,并在1-3℃下搅拌混合8min。
作为本发明再进一步的方案:所述步骤(6)将步骤(5)所得物和步骤(3)所得物加入盐酸氟桂利嗪口服液中,混合搅拌12min后加入羧甲基纤维素钠,继续搅拌8min。
与现有技术相比,本发明的有益效果是:
该西药组合物通过原料复配发挥协同作用,具有疗效好、治疗周期短、毒副作用小、无并发症产生的优点,且制备方法简单,生产成本低,可以有效增强人体免疫力,是一种有效治疗抑郁症的药物;且口感好,有利于患者长期坚持服用。
具体实施方式
下面结合具体实施方式对本专利的技术方案作进一步详细地说明。
实施例1
一种治疗抑郁症的西药组合物,包括以下重量份数的原料:丙咪嗪0.5份,羧甲基纤维素钠2份,阿米替林1份,磷酸二酯酶1份,那格列奈2份,盐酸氟桂利嗪口服液2份,葡醛内酯片2份,甘珀酸钠2份,瓜蒂素2份,利培酮0.5份,奋乃静0.5份,维生素B 0.5份,蒸馏水50份。
一种治疗抑郁症的西药组合物的制备方法,具体步骤为:
(1)按照重量份数称取各原料,备用;
(2)将利培酮、奋乃静研磨成粉末后加入丙咪嗪中,搅拌混合均匀;
(3)将步骤(2)所得物在60℃温度下烘干;
(4)将阿米替林、那格列奈、葡醛内酯片和甘珀酸钠混合后粉碎成粉末,搅拌均匀;
(5)将瓜蒂素、磷酸二酯酶和维生素B分别研磨成粉末,并在0℃下搅拌混合5min;
(6)将步骤(5)所得物和步骤(3)所得物加入盐酸氟桂利嗪口服液中,混合搅拌10min后加入羧甲基纤维素钠,继续搅拌5min;
(7)将步骤(6)所得物放入蒸馏水中,搅拌均匀后,经过压丸、定型、干燥得到西药组合物。
实施例2
一种治疗抑郁症的西药组合物,包括以下重量份数的原料:丙咪嗪2份,羧甲基纤维素钠5份,阿米替林8份,磷酸二酯酶5份,那格列奈5份,盐酸氟桂利嗪口服液8份,葡醛内酯片5份,甘珀酸钠5份,瓜蒂素5份,利培酮2份,奋乃静1份,维生素B 1份,蒸馏水100份。
一种治疗抑郁症的西药组合物的制备方法,具体步骤为:
(1)按照重量份数称取各原料,备用;
(2)将利培酮、奋乃静研磨成粉末后加入丙咪嗪中,搅拌混合均匀;
(3)将步骤(2)所得物在75℃温度下烘干;
(4)将阿米替林、那格列奈、葡醛内酯片和甘珀酸钠混合后粉碎成粉末,搅拌均匀;
(5)将瓜蒂素、磷酸二酯酶和维生素B分别研磨成粉末,并在5℃下搅拌混合10min;
(6)将步骤(5)所得物和步骤(3)所得物加入盐酸氟桂利嗪口服液中,混合搅拌15min后加入羧甲基纤维素钠,继续搅拌10min;
(7)将步骤(6)所得物放入蒸馏水中,搅拌均匀后,经过压丸、定型、干燥得到西药组合物。
实施例3
一种治疗抑郁症的西药组合物,包括以下重量份数的原料:丙咪嗪0.8份,羧甲基纤维素钠3份,阿米替林5份,磷酸二酯酶2份,那格列奈3份,盐酸氟桂利嗪口服液5份,葡醛内酯片3份,甘珀酸钠4份,瓜蒂素3份,利培酮1份,奋乃静0.6份,维生素B 0.7份,蒸馏水80份。
一种治疗抑郁症的西药组合物的制备方法,具体步骤为:
(1)按照重量份数称取各原料,备用;
(2)将利培酮、奋乃静研磨成粉末后加入丙咪嗪中,搅拌混合均匀;
(3)将步骤(2)所得物在65℃温度下烘干;
(4)将阿米替林、那格列奈、葡醛内酯片和甘珀酸钠混合后粉碎成粉末,搅拌均匀;
(5)将瓜蒂素、磷酸二酯酶和维生素B分别研磨成粉末,并在2℃下搅拌混合8min;
(6)将步骤(5)所得物和步骤(3)所得物加入盐酸氟桂利嗪口服液中,混合搅拌12min后加入羧甲基纤维素钠,继续搅拌8min。
(7)将步骤(6)所得物放入蒸馏水中,搅拌均匀后,经过压丸、定型、干燥得到西药组合物。
对比例1
一种治疗抑郁症的西药组合物,包括以下重量份数的原料:丙咪嗪0.8份,羧甲基纤维素钠3份,阿米替林5份,磷酸二酯酶2份,那格列奈3份,盐酸氟桂利嗪口服液5份,甘珀酸钠4份,瓜蒂素3份,利培酮1份,奋乃静0.6份,维生素B 0.7份,蒸馏水80份。
一种治疗抑郁症的西药组合物的制备方法,具体步骤为:
(1)按照重量份数称取各原料,备用;
(2)将利培酮、奋乃静研磨成粉末后加入丙咪嗪中,搅拌混合均匀;
(3)将步骤(2)所得物在65℃温度下烘干;
(4)将阿米替林、那格列奈和甘珀酸钠混合后粉碎成粉末,搅拌均匀;
(5)将瓜蒂素、磷酸二酯酶和维生素B分别研磨成粉末,并在2℃下搅拌混合8min;
(6)将步骤(5)所得物和步骤(3)所得物加入盐酸氟桂利嗪口服液中,混合搅拌12min后加入羧甲基纤维素钠,继续搅拌8min。
(7)将步骤(6)所得物放入蒸馏水中,搅拌均匀后,经过压丸、定型、干燥得到西药组合物。
对比例2
一种治疗抑郁症的西药组合物,包括以下重量份数的原料:丙咪嗪0.8份,羧甲基纤维素钠3份,阿米替林5份,磷酸二酯酶2份,那格列奈3份,盐酸氟桂利嗪口服液5份,葡醛内酯片3份,甘珀酸钠4份,利培酮1份,奋乃静0.6份,维生素B 0.7份,蒸馏水80份。
一种治疗抑郁症的西药组合物的制备方法,具体步骤为:
(1)按照重量份数称取各原料,备用;
(2)将利培酮、奋乃静研磨成粉末后加入丙咪嗪中,搅拌混合均匀;
(3)将步骤(2)所得物在65℃温度下烘干;
(4)将阿米替林、那格列奈、葡醛内酯片和甘珀酸钠混合后粉碎成粉末,搅拌均匀;
(5)磷酸二酯酶和维生素B分别研磨成粉末,并在2℃下搅拌混合8min;
(6)将步骤(5)所得物和步骤(3)所得物加入盐酸氟桂利嗪口服液中,混合搅拌12min后加入羧甲基纤维素钠,继续搅拌8min。
(7)将步骤(6)所得物放入蒸馏水中,搅拌均匀后,经过压丸、定型、干燥得到西药组合物。
采用本发明实施例1-3和对比例1-2制备的西药组合物治疗抑郁症的试验研究:
作为实验患者的抑郁症患者,按如下诊断标准确诊:(1)反复出现言语性幻听;2)明显的思维松弛、思维破裂、言语不连贯,或思维内容贫乏;(3)思想被插入、被撤走、被播散、思维中断,或强制性思维;(4)被动、被控制,或被洞悉体验;(5)原发性妄想(包括妄想知觉,妄想心境)或其他荒谬的妄想;(6)思维逻辑倒错、病理性象征性思维,或语词新作;(7)情感倒错,或明显的情感淡漠;(8)紧张综合征、怪异行为,或愚蠢行为;(9)明显的意志减退或缺乏。排除器质性精神障碍,及精神活性物质和非成瘾物质所致精神障碍。
将120例抑郁症患者,随机分为6组,每组20人,分别实验1组、实验2组、实验3组、实验4组、实验5组和对照组;年龄18-60岁,病程6个月到l0年。6组病例性别、年龄、病程等资料,差异无统计学意义(P>0.05),有可比性。
实验1组每日口服实施例1制备的西药组合物,一次2-3g,一日两次,3个月为一个疗程,治疗一个疗程后出院;实验2组每日口服实施例2制备的西药组合物,一次2-3g,一日两次,3个月为一个疗程,治疗一个疗程后出院;实验3组每日口服实施例3制备的西药组合物,一次2-3g,一日两次,3个月为一个疗程,治疗一个疗程后出院;实验4组每日口服对比例1制备的西药组合物,一次2-3g,一日两次,3个月为一个疗程,治疗一个疗程后出院;实验5组每日口服对比例2制备的西药组合物,一次2-3g,一日两次,3个月为一个疗程,治疗一个疗程后出院;对照组每日口服利培酮,按照说明书服用,治3个月后出院。且6组出院后均坚持继续服用,于出院时、6个月、1年作出3个时段的疗效评价。
疗效标准拟定如下:
显效:服用1个疗程后,症状完全或基本消失,自知力存在;
有效:服用1个疗程后,症状基本消失,部分自知力存在;
无效:服用1个疗程后,症状毫无减轻,自知力未恢复。
6组病例均于入院时和出院时接受《精神症状评定量表》(BPRS)评分;并于6个月和1年跟踪随访,用《治疗时出现的症状量表)(TESS)进行疗效综合评定(参考张明圆《精神科评定量表手册》[M].北京:人民卫生出版社,2003:81-93,151-152,197-201。)6组患者的BPRS总分和TESS疗效评定比较参见表1、表2。
表1 6组BPRS总分变化比较
组别 | 病例数 | 入院时分值 | 出院时分值 |
实验1组 | 20 | 34.5±2.3 | 18.5±1.5 |
实验2组 | 20 | 33.9±3.1 | 18.3±2.0 |
实验3组 | 20 | 33.6±2.5 | 18.0±1.3 |
实验4组 | 20 | 34.1±3.5 | 17.9±1.0 |
实验5组 | 20 | 35.0±2.8 | 18.2±1.6 |
对照组 | 20 | 33.5±3.6 | 19.8±2.8 |
表2 6组TESS疗效评定比较
实验1-3组表示实验1组、实验2组和实验3组的平均值。显效、有效单位:例;有效率单位:%。对比例1中未添加葡醛内酯片,对比例2中未添加瓜蒂素。
有表1-2可以看出,实验1-3组的治疗效果显著优于实验4-5组;且实验1-3组的治疗效果优于对照组,是一种有效的治疗抑郁症的西药组合物。
该西药组合物通过原料复配发挥协同作用,具有疗效好、治疗周期短、毒副作用小、无并发症产生的优点,且制备方法简单,生产成本低,可以有效增强人体免疫力,是一种有效治疗抑郁症的药物;且口感好,有利于患者长期坚持服用。
上面对本专利的较佳实施方式作了详细说明,但是本专利并不限于上述实施方式,在本领域的普通技术人员所具备的知识范围内,还可以在不脱离本专利宗旨的前提下做出各种变化。
Claims (6)
1.一种治疗抑郁症的西药组合物,其特征在于,包括以下重量份数的原料:丙咪嗪0.5-2份,羧甲基纤维素钠2-5份,阿米替林1-8份,磷酸二酯酶1-5份,那格列奈2-5份,盐酸氟桂利嗪口服液2-8份,葡醛内酯片2-5份,甘珀酸钠2-5份,瓜蒂素2-5份,利培酮0.5-2份,奋乃静0.5-1份,维生素B 0.5-1份,蒸馏水50-100份。
2.根据权利要求1所述的治疗抑郁症的西药组合物,其特征在于,包括以下重量份数的原料:丙咪嗪0.8份,羧甲基纤维素钠3份,阿米替林5份,磷酸二酯酶2份,那格列奈3份,盐酸氟桂利嗪口服液5份,葡醛内酯片3份,甘珀酸钠4份,瓜蒂素3份,利培酮1份,奋乃静0.6份,维生素B 0.7份,蒸馏水80份。
3.一种如权利要求1-2任一所述的治疗抑郁症的西药组合物的制备方法,其特征在于,具体步骤为:
(1)按照重量份数称取各原料,备用;
(2)将利培酮、奋乃静研磨成粉末后加入丙咪嗪中,搅拌混合均匀;
(3)将步骤(2)所得物在60-75℃温度下烘干;
(4)将阿米替林、那格列奈、葡醛内酯片和甘珀酸钠混合后粉碎成粉末,搅拌均匀;
(5)将瓜蒂素、磷酸二酯酶和维生素B分别研磨成粉末,并在0-5℃下搅拌混合5-10min;
(6)将步骤(5)所得物和步骤(3)所得物加入盐酸氟桂利嗪口服液中,混合搅拌10-15min后加入羧甲基纤维素钠,继续搅拌5-10min;
(7)将步骤(6)所得物放入蒸馏水中,搅拌均匀后,经过压丸、定型、干燥得到西药组合物。
4.根据权利要求3所述的治疗抑郁症的西药组合物的制备方法,其特征在于,所述步骤(3)将步骤(2)所得物在65℃温度下烘干。
5.根据权利要求3所述的治疗抑郁症的西药组合物的制备方法,其特征在于,所述步骤(5)将瓜蒂素、磷酸二酯酶和维生素B分别研磨成粉末,并在1-3℃下搅拌混合8min。
6.根据权利要求3所述的治疗抑郁症的西药组合物的制备方法,其特征在于,所述步骤(6)将步骤(5)所得物和步骤(3)所得物加入盐酸氟桂利嗪口服液中,混合搅拌12min后加入羧甲基纤维素钠,继续搅拌8min。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611077607.5A CN106729652A (zh) | 2016-11-30 | 2016-11-30 | 一种治疗抑郁症的西药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611077607.5A CN106729652A (zh) | 2016-11-30 | 2016-11-30 | 一种治疗抑郁症的西药组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106729652A true CN106729652A (zh) | 2017-05-31 |
Family
ID=58898819
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611077607.5A Withdrawn CN106729652A (zh) | 2016-11-30 | 2016-11-30 | 一种治疗抑郁症的西药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106729652A (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101460145A (zh) * | 2006-06-16 | 2009-06-17 | Lts罗曼治疗方法有限公司 | 抗抑郁剂组合物干胶片 |
-
2016
- 2016-11-30 CN CN201611077607.5A patent/CN106729652A/zh not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101460145A (zh) * | 2006-06-16 | 2009-06-17 | Lts罗曼治疗方法有限公司 | 抗抑郁剂组合物干胶片 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Adib-Hajbaghery et al. | The effects of chamomile extract on sleep quality among elderly people: A clinical trial | |
Walanj et al. | Efficacy and safety of the topical use of intranasal cinnamon bark extract in seasonal allergic rhinitis patients: A double-blind placebo-controlled pilot study | |
CN107997174A (zh) | 一种具有改善睡眠和/或抗抑郁功效的保健组合物和保健食品 | |
CN106880839B (zh) | 一种鹿骨片及其制备方法 | |
CN103463624A (zh) | 一种骨关节复合营养强化剂及其制备方法 | |
CN106729652A (zh) | 一种治疗抑郁症的西药组合物及其制备方法 | |
CN108042653A (zh) | 一种抗疲劳醒神植物棉片及其制备工艺 | |
CN106390102A (zh) | 一种治疗精神分裂症的西药组合物 | |
CN104435100B (zh) | 一种抗抑郁组合物 | |
CN106581653A (zh) | 一种治疗精神分裂症的药物组合物 | |
CN106806244A (zh) | 一种瓜拉那瘦身身体乳 | |
CN106236696B (zh) | 一种含有叶绿素的舒敏保湿水 | |
CN104257790B (zh) | 一种复方枣仁胶囊的新用途 | |
CN106924445A (zh) | 一种辅助睡眠外用生物制剂及其制备方法 | |
CN107874241A (zh) | 一种改善睡眠的保健食品及其制备方法 | |
Meresh et al. | Psychotropics and neuroprotection: literature review and case series report | |
Babaei et al. | Preoperative oral valiflore reduces anxiety in laparoscopic cholecystectomy: a double blind, placebo controlled study | |
CN104623382A (zh) | 一种治疗痰热内扰型失眠的中药 | |
CN104688823B (zh) | 一种抗菌消炎止痒的中药组合物及其制备方法 | |
CN108478635A (zh) | 治疗面瘫的中药组合物及其制备方法与应用 | |
CN107375607A (zh) | 一种治疗抑郁症的药物 | |
CN106727616A (zh) | 一种治疗精神分裂症的药物 | |
CN106727932A (zh) | 一种治疗精神分裂症的中西药组合物 | |
CN106727695A (zh) | 一种治疗精神分裂症的药物组合物及其制备方法和应用 | |
Choi et al. | Central effects of rat versus mouse leptin: ingestive behavior and adipose apoptosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170531 |
|
WW01 | Invention patent application withdrawn after publication |